It was reported that by targeting low-density lipoprotein-related receptor 6 (LRP6) to promote the WNT signaling pathway, miR-21 production could be inhibited to treat NAFLD [199]. The gene discussed is LRP6; the disease is metabolic dysfunction-associated steatotic liver disease.